Ziprasidone: Efficacy and safety in patients with bipolar disorder

Expert Review of Neurotherapeutics

Volumn 6, Issue 8, 2006, Pages 1129-1138

  Patel, Nick C ^a   Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute mania; Atypical antipsychotic; Bipolar disorder; Ziprasidone

Indexed keywords

ALDEHYDE OXIDASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR AFFECTING AGENT; HALOPERIDOL; KETOCONAZOLE; LITHIUM; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGITATION; AKATHISIA; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIVER METABOLISM; MANIA; META ANALYSIS; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MUSCLE HYPERTONIA; NAUSEA; PEDIATRICS; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREMOR; VISUAL DISORDER; VOMITING;

BIPOLAR DISORDER; DOPAMINE ANTAGONISTS; HUMANS; PIPERAZINES; THIAZOLES;

EID: 33747159594     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.8.1129     Document Type: Review

References (57)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition Text Revision (DSM-IV TR). American Psychiatric Association, Washington, DC, USA (2000).
2. Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276(4), 293-299 (1996).
3. Woods SW. The economic burden of bipolar disease. J. Clin. Psychiatry 61(Suppl. 13), 38-41 (2000).
4. Stimmel GL. Economic grand rounds: the economic burden of bipolar disorder. Psychiatr. Serv. 55(2), 117-118 (2004).
5. Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am. J. Psychiatry 162(5), 1008-1010 (2005).
6. McElroy SL, Altshuler LL, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. J. Psychiatry 158(3), 420-426 (2001).
7. Valtonen H, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa ET. Suicidal ideation and attempts in bipolar I and II disorders. J. Clin. Psychiatry 66(11), 1456-1462 (2005).
8. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64(2), 161-174 (2003).
9. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 163(2), 217-224 (2006).
10. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr. Scand. 105(3), 164-172 (2002).
11. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271(12), 918-924 (1994).
12. Weisler RH, Kalali AH, Ketter TA, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry 65(4), 478-484 (2004).
13. Weisler RH, Keck PE Jr, Swann AC et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 66(3), 323-330 (2005).
14. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60(4), 392-400 (2003).
15. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64(9), 1013-1024 (2003).
16. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 67(4), 509-516 (2006).
17. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K, Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry 160(4), 741-748 (2003).
18. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, doubleblind, placebo-controlled replication trial. J. Clin. Psychopharmacol. 25(4), 301-310 (2005).
19. Weisler R, Dunn J, English P. Ziprasidone in adjunctive treatment of acute bipolar mania: double-blind, placebo-controlled trial. Presented at the 55th Institute on Psychiatric Services Meeting, Boston, MA, USA (2003).
20. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66(7), 870-886 (2005).
21. Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J. Clin. Psychiatry 62(9), 670-671 (2001).
22. Yatham LN. Translating knowledge of genetics and pharmacology into improving everyday practice. Bipolar Disord. 7(Suppl. 4), 13-20 (2005).
23. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin. Pharmacokinet. 44(11), 1117-1133 (2005).
24. Keck PE Jr, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Expert Opin. Pharmacother. 2(6), 1033-1042 (2001).
25. Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J. Clin. Psychiatry 63(Suppl. 4), 3-11 (2002).
26. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425(3), 197-201 (2001).
27. Seeger TF, Seymour PA, Schmidt AW et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor activity. J. Pharmacol. Exp. Ther. 275(1), 101-113 (1995).
28. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161(5), 818-825 (2004).
29. (1A) receptors. J. Pharmacol. Exp. Ther. 295(3), 853-861 (2000).
30. Hamelin BA, Allard S, Laplante L et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18(1), 9-15 (1998).
31. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br. J. Clin. Pharmacol. 49(Suppl. 1), S5-S13 (2000).
32. Wilner KD, Tensfeldt TG, Baris B et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. 49(Suppl. 1), S15-S20 (2000).
33. Aweeka F, Jayesekara D, Horton M et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br. J. Clin. Pharmacol. 49(Suppl. 1), S27-S33 (2000).
34. Everson G, Lasseter KC, Anderson KE et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br. J. Clin. Pharmacol. 49(Suppl. 1), S21-S26 (2000).
35. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann. Pharmacother. 36(5), 839-851 (2002).
36. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol. 23(3), 229-232 (2003).
37. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo-controlled crossover study in healthy volunteers. Br. J. Clin. Pharmacol. 49(Suppl. 1), S71-S76 (2000).
38. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady state pharmacokinetics of ziprasidone in healthy volunteers. Br. J. Clin. Pharmacol. 49(Suppl. 1), S65-S70 (2000).
39. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br. J. Clin. Pharmacol. 49(Suppl. 1), S35-S42 (2000).
40. Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J. Clin. Pharmacol. 45(6), 620-630 (2005).
41. Keck PE Jr, Potkin S, Warrington L, Loebel A, Giller E, Batzar E. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Presented at the 157th Annual Meeting of the American Psychiatric Association, New York, NY, USA (2004).
42. Weisler R, Warrington L, Dunn J, Giller EL, Mandel FS. Adjunctive ziprasidone in bipolar mania: short- and long-term data. Presented at the 157th Annual Meeting of the American Psychiatric Association, New York, NY, USA (2004).
43. Versavel M, DelBello MP, Ice K, Kowatch R, Keller D, Miceli J. Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder. Neuropsychopharmacology 30(Suppl. 1), S122 (2005).
44. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.) 155(2), 128-134 (2001).
45. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J. Clin. Psychiatry 62(1), 12-18 (2001).
46. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J. Clin. Psychiatry 61(12), 933-941 (2000).
47. Daniel DG, Zimbroff DL, Swift RH, Harrigan EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int. Clin. Psychopharmacol. 19(1), 9-15 (2004).
48. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am. J. Health Syst. Pharm. 57(3), 238-255 (2000).
49. Weiden PJ. Ziprasidone: a new atypical antipsychotic. J. Psychiatr. Pract. 7(2), 145-153 (2001).
50. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596-601 (2004).
51. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J. Clin. Psychopharmacol. 24(4), 429-436 (2004).
52. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J. Clin. Psychiatry 65(Suppl. 6), 20-29 (2004).
53. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry 65(2), 217-221 (2004).
54. Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J. Clin. Psychiatry 65(11), 1537-1545 (2004).
55. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 7(Suppl. 4), 21-33 (2005).
56. Keck PE Jr. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J. Clin. Psychiatry 66(Suppl. 3), 5-11 (2005).
57. Pfizer's official website www.pfizer.com/pfizer/are/news_releases/2005pr/ mn_2005_1031.jsp